Application of metabolomics based on direct mass spectrometry analysis for the elucidation of altered metabolic pathways in serum from the APP/PS1 transgenic model of Alzheimer's disease

Journal of Pharmaceutical and Biomedical Analysis

Volumn 107, Issue , 2015, Pages 378-385

  González Domínguez, Raúl ^a   García Barrera, Tamara ^a   Vitorica, Javier ^b,c,d   Gómez Ariza, José Luis ^a  

^a UNIVERSITY OF HUELVA   (Spain)

^b UNIVERSITY OF SEVILLE   (Spain)

^c CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

^d Instituto de Biomedicina de Sevilla   (Spain)

Author keywords

Alzheimer's disease; APP PS1 mice; DI ESI MS; FI APPI MS; Metabolomics

Indexed keywords

AMYLOID PRECURSOR PROTEIN; BIOLOGICAL MARKER; CHOLESTEROL ESTER; CHOLINE; DIACYLGLYCEROL; FATTY ACID; GLYCEROPHOSPHOETHANOLAMINE; ICOSANOID; INOSINE; PHOSPHOETHANOLAMINE; PHOSPHOLIPID; PHOSPHORYLCHOLINE; PRESENILIN 1; TRIACYLGLYCEROL; UREA;

ALZHEIMER DISEASE; ANIMAL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATMOSPHERIC PRESSURE; BLOOD; BRAIN; C57BL MOUSE; CONTROLLED STUDY; DISEASE MODEL; ELECTROSPRAY MASS SPECTROMETRY; EXTRACTION; FEMALE; MALE; MASS SPECTROMETRY; METABOLISM; METABOLOME; METABOLOMICS; MOUSE; NONHUMAN; PHYSIOLOGY; PRIORITY JOURNAL; PROCEDURES; PROTEIN BLOOD LEVEL; PROTEIN METABOLISM; SERUM; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; ATMOSPHERIC PRESSURE; BIOMARKERS; BLOOD; BRAIN; DISEASE MODELS, ANIMAL; FEMALE; MALE; MASS SPECTROMETRY; METABOLIC NETWORKS AND PATHWAYS; METABOLISM; METABOLOME; METABOLOMICS; METHODS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PHOSPHOLIPIDS; PHYSIOLOGY; PRESENILIN-1; SERUM;

EID: 84964222409     PISSN: 07317085     EISSN: 1873264X     Source Type: Journal    
DOI: 10.1016/j.jpba.2015.01.025     Document Type: Article

References (57)

1. McGonigle P., Ruggeri B. Animal models of human disease: challenges in enabling translation. Biochem. Pharmacol. 2014, 87:162-171.
2. Hall A.M., Roberson E.D. Mouse models of Alzheimer's disease. Brain Res. Bull. 2012, 88:3-12.
3. Trushina E., Mielke M.M. Recent advances in the application of metabolomics to Alzheimer's disease. Biochim. Biophys. Acta 2014, 1842:1232-1239.
4. Salek R.M., Xia J., Innes A., Sweatman B.C., Adalbert R., Randle S., McGowan E., Emson P.C., Griffin J.L. A metabolomic study of the CRND8 transgenic mouse model of Alzheimer's disease. Neurochem. Int. 2010, 56:937-943.
5. Lin S., Liu H., Kanawati B., Liu L., Dong J., Li M., Huang J., Schmitt-Kopplin P., Cai Z. Hippocampal metabolomics using ultrahigh-resolution mass spectrometry reveals neuroinflammation from Alzheimer's disease in CRND8 mice. Anal. Bioanal. Chem. 2013, 405:5105-5117.
6. Lin S., Kanawati B., Liu L., Witting M., Li M., Huang J., Schmitt-Kopplin P., Cai Z. Ultra high resolution mass spectrometry-based metabolic characterization reveals cerebellum as a disturbed region in two animal models. Talanta 2014, 118:45-53.
7. Trushina E., Nemutlu E., Zhang S., Christensen T., Camp J., Mesa J., Siddiqui A., Tamura Y., Sesaki H., Wengenack T.M., Dzeja P.P., Poduslo J.F. Defects in mitochondrial dynamics and metabolomic signatures of evolving energetic stress in mouse models of familial Alzheimer's disease. PLoS ONE 2012, 7:e32737.
8. González-Domínguez R., García-Barrera T., Vitorica J., Gómez-Ariza J.L. Region-specific metabolic alterations in the brain of the APP/PS1 transgenic mice of Alzheimer's disease. Biochim. Biophys. Acta 2014, 1842:2395-2402.
9. González-Domínguez R., García-Barrera T., Vitorica J., Gómez-Ariza J.L. Metabolomic screening of regional brain alterations in the APP/PS1 transgenic mouse model of Alzheimer's disease by direct infusion mass spectrometry. J. Pharm. Biomed. Anal. 2015, 102:425-435.
10. 1H NMR metabolomics investigation of an Alzheimer's disease (AD) mouse model pinpoints important biochemical disturbances in brain and plasma. Metabolomics 2013, 9:974-983.
11. Hu Z.P., Browne E.R., Liu T., Angel T.E., Ho P.C., Chan E.C.Y. Metabonomic profiling of TASTPM transgenic alzheimer's disease mouse model. J. Proteome Res. 2012, 11:5903-5913.
12. Jiang N., Yan X., Zhou W., Zhang Q., Chen H., Zhang Y., Zhang X. NMR-based metabonomic investigations into the metabolic profile of the senescence-accelerated mouse. J. Proteome Res. 2008, 7:3678-3686.
13. Fukuhara K., Ohno A., Ota Y., Senoo Y., Maekawa K., Okuda H., Kurihara M., Okuno A., Niida S., Saito Y., Takikawa O. NMR-based metabolomics of urine in a mouse model of Alzheimer's disease: identification of oxidative stress biomarkers. J. Clin. Biochem. Nutr. 2013, 52:133-138.
14. Gonzalez-Dominguez R., Castilla-Quintero R., Garcia-Barrera T., Gomez-Ariza J.L. Development of a metabolomic approach based on urine samples and direct infusion mass spectrometry. Anal. Biochem. 2014, 465:20-27.
15. Peng J., Guo K., Xia J., Zhou J., Yang J., Westaway D., Wishart D.S., Li L. Development of isotope labeling liquid chromatography mass spectrometry for mouse urine metabolomics: quantitative metabolomic study of transgenic mice related to Alzheimer's disease. J. Proteome Res. 2014, 13:4457-4469.
16. Draper J., Lloyd A.J., Goodacre R., Beckmann M. Flow infusion electrospray ionisation mass spectrometry for high throughput, non-targeted metabolite fingerprinting: a review. Metabolomics 2013, 9:S4-S29.
17. Gonzalez-Dominguez R., Garcia-Barrera T., Gomez-Ariza J.L. Metabolomic approach to Alzheimer's disease diagnosis based on mass spectrometry. Chem. Papers 2012, 66:829-835.
18. González-Domínguez R., García-Barrera T., Gómez-Ariza J.L. Using direct infusión mass spectrometry forserum metabolomics in Alzheimer's disease. Anal. Bioanal. Chem. 2014, 406:7137-7148.
19. González-Domínguez R., García-Barrera T., Gómez-Ariza J.L. Metabolomic study of lipids in serum for biomarker discovery in Alzheimer's disease using direct infusion mass spectrometry. J. Pharm. Biomed. Anal. 2014, 98:321-326.
20. González-Domínguez R., Garcia-Barrera T., Gomez-Ariza J.L. Application of a novel metabolomic approach based on atmospheric pressure photoionization mass spectrometry using flow injection analysis for the study of Alzheimer's disease. Talanta 2015, 131:480-489.
21. Jankowsky J.L., Fadale D.J., Anderson J., Xu G.M., Gonzales V., Jenkins N.A., Copeland N.G., Lee M.K., Younkin L.H., Wagner S.L., Younkin S.G., Borchelt D.R. Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific g secretase. Hum. Mol. Genet. 2004, 13:159-170.
22. Sangster T., Major H., Plumb R., Wilson A.J., Wilson I.D. A pragmatic and readily implemented quality control strategy for HPLC-MS and GC-MS-based metabonomic analysis. Analyst 2006, 131:1075-1078.
23. van den Berg R.A., Hoefsloot H.C.J., Westerhuis J.A., Smilde A.K., van der Werf M.J. Centering, scaling, and transformations: improving the biological information content of metabolomics data. BMC Genomics 2006, 7:142.
24. Xia J., Broadhurst D.I., Wilson M., Wishart D.S. Translational biomarker discovery in clinical metabolomics: an introductory tutorial. Metabolomics 2013, 9:280-299.
25. Pulfer M., Murphy R.C. Electrospray mass spectrometry of phospholipids. Mass Spectrom. Rev. 2003, 22:332-364.
26. Wang C., Xie S., Yang J., Yang Q., Xu G. Structural identification of human blood phospholipids using liquid chromatography/quadrupole-linear ion trap mass spectrometry. Anal. Chim. Acta 2004, 525:1-10.
27. González-Dominguez R., García-Barrera T., Gómez-Ariza J.L. Iberian ham typification by direct infusion electrospray and photospray ionization mass spectrometry fingerprinting. Rapid Commun. Mass Spectrom. 2012, 26:835-844.
28. Liebisch G., Binder M., Schifferer R., Langmann T., Schulz B., Schmitz G. High throughput quantification of cholesterol and cholesteryl ester by electrospray ionization tandem mass spectrometry (ESI-MS/MS). Biochim. Biophys. Acta 2006, 1761:121-128.
29. Vernez L., Hopfgartner G., Wenk M., Krahenbuhl S. Determination of carnitine and acylcarnitines in urine by high-performance liquid chromatography-electrospray ionization ion trap tandem mass spectrometry. J. Chromatogr. A 2003, 984:203-213.
30. Murphy R.C., Barkley R.M., Berry K.Z., Hankin J., Harrison K., Johnson C., Krank J., McAnoy A., Uhlson C., Zarini S. Electrospray ionization and tandem mass spectrometry of eicosanoids. Anal. Biochem. 2005, 346:1-42.
31. Trushina E., Dutta T., Persson X.M.T., Mielke M.M., Petersen R.C. Identification of altered betabolic pathways in plasma and CSF in mild cognitive impairment and Alzheimer's disease using metabolomics. PLoS ONE 2013, 8:e63644.
32. Wang G., Zhou Y., Huang F.J., Tang H.D., Xu X.H., Liu J.J., Wang Y., Deng Y.L., Ren R.J., Xu W., Ma J.F., Zhang Y.N., Zhao A.H., Chen S.D., Jia W. Plasma metabolite profiles of Alzheimer's disease and mild cognitive impairment. J. Proteome Res. 2014, 13:2649-2658.
33. González-Domínguez R., García-Barrera T., Gómez-Ariza J.L. Metabolite profiling for the identification of altered metabolic pathways in Alzheimer's disease. J. Pharm. Biomed. Anal. 2015, 107:75-81.
34. Hipkiss A.R. Could carnosine or related structures suppress Alzheimer's disease?. J. Alzheimers Dis. 2007, 11:229-240.
35. Nuutinen S., Panula P. Histamine in neurotransmission and brain diseases. Adv. Exp. Med. Biol. 2010, 709:95-107.
36. González-Domínguez R., García A., García-Barrera T., Barbas C., Gómez-Ariza J.L. Metabolomic profiling of serum in the progression of Alzheimer's disease by capillary electrophoresis-mass spectrometry. Electrophoresis 2014, 35:3321-3330.
37. Tohgi H., Abe T., Takahashi S., Kimura M., Takahashi J., Kikuchi T. Concentrations of serotonin and its related substances in the cerebrospinal fluid in patients with Alzheimer type dementia. Neurosci. Lett. 1992, 141:9-12.
38. Storga D., Vrecko K., Birkmayer J.G.D., Reibnegger G. Monoaminergic neurotransmitters, their precursors and metabolites in brains of Alzheimer patients. Neurosci. Lett. 1996, 203:29-32.
39. Felipo V., Butterworth R.F. Neurobiology of ammonia. Prog. Neurobiol. 2002, 67:259-279.
40. Hansmannel F., Sillaire A., Kamboh M.I., Lendon C., Pasquier F., Hannequin D., Laumet G., Mounier A., Ayral A.M., DeKosky S.T., Hauw J.J., Berr C., Mann D., Amouyel P., Campion D., Lambert J.C. Is the urea cycle involved in Alzheimer's disease?. J. Alzheimers Dis. 2010, 21:1013-1021.
41. McFarland N.R., Burdett T., Desjardins C.A., Frosch M.P., Schwarzschild M.A. Postmortem brain levels of urate and precursors in Parkinson's disease and related disorders. Neurodegener. Dis. 2013, 12:189-198.
42. 1H NMR analysis of the polar metabolome of post-mortem brain tissue. Metabolomics 2014, 10:744-753.
43. Ibáñez C., Simó C., Martín-Álvarez P.J., Kivipelto M., Winblad B., Cedazo-Mínguez A., Cifuentes A. Toward a predictive model of Alzheimer's disease progression using capillary electrophoresis-mass spectrometry metabolomics. Anal. Chem. 2012, 84:8532-8540.
44. 2. Neurochem. Res. 2004, 29:1961-1977.
45. Gonzalez-Dominguez R., Garcia-Barrera T., Gomez-Ariza J.L. Combination of metabolomic and phospholipid-profiling approaches for the study of Alzheimer's disease. J. Proteomics 2014, 104:37-47.
46. Yao J.K., Wengenack T.M., Curran G.L., Poduslo J.F. Reduced membrane lipids in the cortex of Alzheimer's disease transgenic mice. Neurochem. Res. 2009, 34:102-108.
47. Han X., Holtzman D.M., McKeel D.W. Plasmalogen deficiency in early Alzheimer's disease subjects and in animal models: molecular characterization using electrospray ionization mass spectrometry. J. Neurochem. 2001, 77:1168-1180.
48. Chan R.B., Oliveira T.G., Cortes E.P., Honig L.S., Duff K.E., Small S.A., Wenk M.R., Shui G., Di Paolo G. Comparative lipidomic analysis of mouse and human brain with Alzheimer disease. J. Biol. Chem. 2012, 287:2678-2688.
49. Li N., Liu W., Li W., Li S., Chen X., Bi K., He P. Plasma metabolic profiling of Alzheimer's disease by liquid chromatography/mass spectrometry. Clin. Biochem. 2010, 43:992-997.
50. Shimohama S., Sasaki Y., Fujimoto S., Kamiya S., Taniguchi T., Takenawa T., Kimura J. Phospholipase C isoenzymes in the human brain and their changes in Alzheimer's disease. Neuroscience 1998, 82:999-1007.
51. Jin J.K., Kim N.H., Lee Y.J., Kim Y.S., Choi E.K., Kozlowski P.B., Park M.H., Kim H.S., Min D.S. Phospholipase D1 is up-regulated in the mitochondrial fraction from the brains of Alzheimer's disease patients. Neurosci. Lett. 2006, 407:263-267.
52. 31P MRS of PCA extracts of postmortem Alzheimer's disease brain. Neurobiol. Aging 1996, 17:349-357.
53. Walter A., Korth U., Hilgert M., Hartmann J., Weichel O., Hilgert M., Fassbender K., Schmitt A., Klein J. Glycerophosphocholine is elevated in cerebrospinal fluid of Alzheimer patients. Neurobiol. Aging 2004, 25:1299-1303.
54. Ellison D.W., Beal M.F., Martin J.B. Phosphoethanolamine and ethanolamine are decreased in Alzheimer's disease and Huntington's disease. Brain Res. 1987, 417:389-392.
55. Wang D.C., Sun C.H., Liu L.Y., Sun X.H., Jin X.W., Song W.L., Liu X.Q., Wan X.L. Serum fatty acid profiles using GC-MS and multivariate statistical analysis: potential biomarkers of Alzheimer's disease. Neurobiol. Aging 2012, 33:1057-1066.
56. Fabelo N., Martín V., Marín R., Santpere G., Aso E., Ferrer I., Díaz M. Evidence for premature lipid raft aging in APP/PS1 double-transgenic mice, a model of familial Alzheimer disease. J. Neuropathol. Exp. Neurol. 2012, 71:868-881.
57. Tajima Y., Ishikawa M., Maekawa K., Murayama M., Senoo Y., Nishimaki-Mogami T., Nakanishi H., Ikeda K., Arita M., Taguchi R., Okuno A., Mikawa R., Niida S., Takikawa O., Saito Y. Lipidomic analysis of brain tissues and plasma in a mouse model expressing mutated human amyloid precursor protein/tau for Alzheimer's disease. Lipids Health Dis. 2013, 12:68.